Targeting immune cells to improve cancer treatments
Research Program: Immune Regulation Targets (IRT)
['FUNDING_P30'] · THOMAS JEFFERSON UNIVERSITY · NIH-11072026
This program develops ways to direct immune cells so cancer treatments work better for people with cancers like colon cancer and multiple myeloma.
Quick facts
| Phase | ['FUNDING_P30'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | THOMAS JEFFERSON UNIVERSITY (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11072026 on ClinicalTrials.gov |
What this research studies
From a patient perspective, the program studies how different immune cells help or hinder tumor growth and uses that knowledge to create new immune-based treatments. Researchers look for specific features in lymphoid and myeloid cells that can be targeted by therapies and test strategies to improve how immune cells attack cancer. Work combines lab studies, translational projects, and efforts to bring promising approaches toward the clinic. The program also supports training and community outreach to connect research with local patients and providers.
Who could benefit from this research
Good fit: People with cancers targeted by the program—especially colon cancer and multiple myeloma—or those eligible for immunotherapy trials at Thomas Jefferson University would be the most relevant candidates.
Not a fit: People without cancer or with cancers not addressed by the program, and those unable to travel to the study site, are unlikely to benefit directly from this program.
Why it matters
Potential benefit: If successful, this work could lead to more effective and personalized immunotherapies that help more patients respond to cancer treatment.
How similar studies have performed: Immune-based treatments like CAR-T have worked well for some blood cancers, but applying similar immune-targeting approaches more broadly across cancer types remains an active and evolving area of research.
Where this research is happening
PHILADELPHIA, UNITED STATES
- THOMAS JEFFERSON UNIVERSITY — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: EISCHEN, CHRISTINE M. — THOMAS JEFFERSON UNIVERSITY
- Study coordinator: EISCHEN, CHRISTINE M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Center, Cancer Patient, Cancer Treatment